Abstract-The renin-angiotensin system is upregulated with diabetes, and this may contribute to the development of a dilated myopathy. Angiotensin II (Ang II) locally may lead to oxidative damage, activating cardiac cell death. Moreover, diabetes and hypertension could synergistically impair myocardial structure and function. Therefore, apoptosis and necrosis were measured in ventricular myocardial biopsies obtained from diabetic and diabetic-hypertensive patients. Accumulation of a marker of oxidative stress, nitrotyrosine, and Ang II labeling were evaluated quantitatively. The diabetic heart showed cardiac hypertrophy, cavitary dilation, and depressed ventricular performance. These alterations were more severe with diabetes and hypertension. Key Words: oxidative damage Ⅲ renin-angiotensin system Ⅲ nitrotyrosine Ⅲ heart failure N on-insulin-dependent diabetes mellitus (NIDDM) is characterized by the development of a cardiac myopathy that deteriorates with time. 1 This myopathy often manifests itself with diastolic dysfunction, but whether in the absence of coronary artery disease and hypertension, severe ventricular decompensation occurs, remains controversial. Biochemical and mechanical abnormalities of the myocardium have been identified with diabetes. 2-4 However, cardiac hypertrophy shows essentially identical alterations, 5 raising the possibility that diabetes may initially induce a hypertrophic myopathy, which evolves chronically into a dilated form with markedly depressed contractile behavior. Recent observations point to an upregulation of the local renin-angiotensin system (RAS) and the synthesis of angiotensin II (Ang II) as critical factors in the activation of myocyte apoptosis and reactive hypertrophy in a model of insulin-dependent diabetes. 6 Severe hypertension involves stimulation of the systemic and local RAS, 7,8 myocyte loss, and cellular hypertrophy, 9 suggesting that diabetes and hypertension together may synergistically damage the structure and function of the overloaded human heart.
N on-insulin-dependent diabetes mellitus (NIDDM) is characterized by the development of a cardiac myopathy that deteriorates with time. 1 This myopathy often manifests itself with diastolic dysfunction, but whether in the absence of coronary artery disease and hypertension, severe ventricular decompensation occurs, remains controversial. Biochemical and mechanical abnormalities of the myocardium have been identified with diabetes. [2] [3] [4] However, cardiac hypertrophy shows essentially identical alterations, 5 raising the possibility that diabetes may initially induce a hypertrophic myopathy, which evolves chronically into a dilated form with markedly depressed contractile behavior. Recent observations point to an upregulation of the local renin-angiotensin system (RAS) and the synthesis of angiotensin II (Ang II) as critical factors in the activation of myocyte apoptosis and reactive hypertrophy in a model of insulin-dependent diabetes. 6 Severe hypertension involves stimulation of the systemic and local RAS, 7, 8 myocyte loss, and cellular hypertrophy, 9 suggesting that diabetes and hypertension together may synergistically damage the structure and function of the overloaded human heart.
A direct correlation exists between hyperglycemia and oxidative stress. 10, 11 Ang II stimulates the production of reactive O 2 , [12] [13] [14] and the detrimental effects of Ang II with diabetes have been shown clinically 15 and experimentally. 6 Thus, Ang II and oxidative damage may be critical in the onset of a diabetic myopathy. Hypertension may enhance Ang II formation, potentiating the cardiac damage in NIDDM. To address these issues, cell death by apoptosis and necrosis was evaluated in myocardial biopsies obtained from patients with NIDDM alone and in combination with hypertension. Cell death was quantitated separately in myocytes, endothelial cells, and fibroblasts to establish the effects of these diseases on the different cardiac cell populations. Additionally, Ang II labeling and the localization of nitrotyrosine in myocytes, endothelial cells, and fibroblasts were measured quantitatively. Nitrotyrosine was determined, because this modified amino acid is a product of reactive O 2 . 16 
Materials and Methods

Patients
Sixteen men and 7 women with diabetes (11 patients; 57Ϯ10 years of age) or diabetes and hypertension (12 patients; 58Ϯ13 years of age) and New York Heart Association (NYHA) class II through IV were studied. Echocardiography, cardiac catheterization, and coro-nary angiography were performed, and left ventricular (LV) endomyocardial biopsies were obtained. Measurements included LV end-systolic (LVESD) and end-diastolic (LVEDD) diameters, septal (LVST) and posterior (LVPT) LV wall thickness, wall thickness-tochamber radius ratio (LVPT/CR), ejection fraction (EF), fractional shortening (FS), and LV mass (LVM). 17 The study was approved by the institutional review committee, and patients gave informed consent. Ten nondiseased hearts collected at autopsy were used for control morphometric measurements. 18 Autopsy hearts processed several hours after death do not allow estimation of cell necrosis. 19 Baseline cell death was assessed in 10 surgical specimens of papillary muscles from patients with mitral stenosis. This analysis was complemented by cell-death determinations in LV myocardial samples obtained from five additional subjects who died from causes other than cardiovascular diseases and underwent autopsy within 3 to 9 hours after death. 19 
Myocardial Sampling
In all patients, 2 to 3 endomyocardial biopsies, approximately 3 mm 3 each, were collected from the LV and embedded in paraffin. Samples from the LV endomyocardium of 15 autopsy hearts and 10 specimens of papillary muscles were similarly treated. Ang II localization was measured in frozen sections of 1 to 2 biopsies from 8 of the 11 diabetic patients, 5 of the 12 diabetic-hypertensive patients, and 5 of the 10 papillary muscles.
Volume Composition and Myocyte Area
Volume fractions of myocytes and collagen and myocyte crosssectional area were obtained by confocal microscopy in sections with transversely cut myocytes stained with ␣-sarcomeric actin, laminin, and collagen types I and III. 6, 18 
Cell Death and Nitrotyrosine
Terminal deoxynucleotidyl transferase (TdT) and in situ ligation of hairpin probes with single-base 3Ј overhangs or blunt ends were used. 6, 19, 20 Apoptosis was also measured by activated caspase-3 antibody and apoptosis-necrosis by TdT and hairpin with blunt ends. Myocytes, endothelial cells, and fibroblasts were detected by ␣-sarcomeric actin, factor VIII, and vimentin. Nitrotyrosine was identified by nitrotyrosine antibody. Sections treated with 10% peroxynitrite and degraded peroxynitrite were used as positive and negative controls, respectively.
Angiotensin II
Frozen sections were incubated with Ang II antiserum and with FITC-labeled goat anti-rabbit IgG. Specificity was determined by preabsorption of 10 L of antibody with 0.05 mg of antigen. Nonimmune rabbit serum was also used as negative control. The number of Ang II-positive sites per mm 2 of myocytes and endothelial cells was evaluated quantitatively. 21 Positive control consisted of myocardium from diabetic rats; Ang II concentration measured by ELISA in myocytes isolated from these hearts was increased 14-fold. 6 
Statistics
Results are meanϮSD. Significance between two values was determined by Student's t test and among groups by Bonferroni's method; PϽ0.05 was considered significant.
An expanded Materials and Methods section can be found in an online data supplement available at http://www.circresaha.org.
Results
Patients
The duration of diabetes (D) varied from 3 to 12 years, averaging 6 years. Diabetes in hypertensive patients (DH) ranged from 3 to 17 years, with a mean of 12 years. Hypertension lasted 2 to 15 years, with an average of 9 years. Hypertension was a secondary event in 11 of the 12 patients and followed the onset of diabetes by 1 to 8 years. In one patient, hypertension preceded diabetes by one year. In the D group, 4 patients were in NYHA class II, 2 in class III, and 5 in class IV. In the DH group, 2 patients were in class III and 10 in class IV. Blood glucose levels were comparable in the 2 groups: Dϭ190Ϯ39 mg/dL; DHϭ210Ϯ27 mg/dL. Treatment of D consisted of oral hypoglycemic drugs and angiotensin-converting enzyme (ACE) inhibitors. Patients with DH received also diuretics and ␤-blockers. Four D and 8 DH patients were treated with digitalis.
Cardiac Performance
Functional parameters were abnormal in D and DH patients: LVPT (Dϭ9.8Ϯ1.7; DHϭ9.1Ϯ1.8 mm), LVST (Dϭ10.2Ϯ1.7; DHϭ10.9Ϯ1.5 mm), LVEDD (Dϭ65Ϯ5; DHϭ72Ϯ7 mm), LVESD (Dϭ50Ϯ6; DHϭ58Ϯ6 mm), LVPT/CR (Dϭ0.16Ϯ0.02; DHϭ0.13Ϯ0.03 mm/mm), LVM (Dϭ289Ϯ62; DHϭ360Ϯ74 g), FS (Dϭ22Ϯ5; DHϭ19Ϯ4%), and EF (Dϭ32Ϯ9; DHϭ23Ϯ7%). In comparison with diabetes, LVEDD, LVESD, and LVM were 11% (PϽ0.02), 16% (PϽ0.005), and 25% (PϽ0.002) larger with diabetes and hypertension. Moreover, LVPT/CR and EF decreased 23% (PϽ0.04) and 28% (PϽ0.02) more when hypertension was present. Coronary angiography was normal in all 23 patients. This was the essential criterion for inclusion in the study. Patients were not considered for cardiac transplantation at the time of biopsy.
Scarring and Myocyte Hypertrophy
With respect to controls (4.4Ϯ1.5%), interstitial fibrosis increased 18% (5.2Ϯ2%; NS) and 66% (7.3Ϯ2.2%; PϽ0.01) in D and DH hearts, respectively. Corresponding increases in replacement fibrosis were 42% (controlϭ5.5Ϯ1.8; Dϭ7.8Ϯ2.8%, NS) and 134% (DHϭ12.9Ϯ3.6%, PϽ0.001).
Collagen accumulation was 55% (PϽ0.05) greater with DH than with D. Myocyte compartment decreased 7% (PϽ0.001) with D and 14% (PϽ0.001) with DH (not shown). Transverse myocyte area ( Figure 1 ) was 285Ϯ39, 394Ϯ76, and 519Ϯ101 m 2 in control, D, and DH hearts, respectively. Myocytes hypertrophied 38% (PϽ0.02) with D and 82% (PϽ0.001) with DH. With DH, myocytes were 32% (PϽ0.005) larger than with diabetes.
Cell Death
Apoptosis was measured by TdT assay, in situ ligation with a hairpin probe, and activated caspase-3 in combination with TdT. TdT identifies double-strand DNA cleavage with 1-to 4-base 3Ј overhangs. The hairpin probe recognizes internucleosomal DNA cleavage with single-base 3Ј overhang only. 19, 20 Cell necrosis was assessed with a hairpin probe detecting double-strand DNA cleavage with blunt ends. 19 Activated caspase-3 is linked to the stimulation of endonucleases and, thereby, DNA fragmentation. 22 Control values for apoptosis and necrosis in LV myocardium (C 1 , nϭ5) and papillary muscles (C 2 , nϭ10) are illustrated separately in Figures 4A through 4C . These baseline measurements were not statistically different. Therefore, they were averaged for comparisons with the diseased hearts. Diabetes was characterized by an 85-, 61-, and 26-fold increase in apoptosis of myocytes, endothelial cells, and fibroblasts, respectively. Diabetes and hypertension did not increase additionally the level of apoptosis in cardiac cells. Values of myocyte and endothelial cell apoptosis were similar with D and DH but were significantly higher than fibroblast apoptosis in both cases. There was no difference between apoptosis measured by TdT or hairpin probe (Figures 4A and 4B ). Diabetes increased necrosis by 4-fold in myocytes, 9-fold in endothelial cells, and 6-fold in fibroblasts ( Figure 4C ). However, diabetes and hypertension increased this form of cell death by 7-fold in myocytes, 18-fold in endothelial cells, and 6-fold in fibroblasts. Myocyte and endothelial cell necrosis with DH were 2-fold higher than with D alone.
Angiotensin II
Myocardial samples, frozen immediately after dissection, were used for the immunocytochemical localization of Ang II in myocytes and endothelial cells (Figures 5A through 5H ). Myocytes were stained by ␣-sarcomeric actin, and the interstitium was labeled by laminin to outline cell profiles. Endothelial cells were identified by factor VIII only; laminin obscured the detection of Ang II in these small cells. Myocardium from diabetic rats was used as a positive control for Ang II localization. 6 As expected, a several-fold higher level of labeling was found in the animal model ( Figures 5I  and 5J) . Preabsorption of the primary antibody with Ang II resulted in the lack of labeling in human samples (not shown) and rat diabetic left ventricle ( Figures 5K and 5L) . Diabetes in humans increased 3.4-and 3.1-fold Ang II labeling of myocytes and endothelial cells, respectively ( Figure 5M ). Diabetes and hypertension together increased additionally Ϸ2-fold Ang II localization in these cell types. The density of Ang II sites per unit area of cell was 5-to 6-fold higher in endothelial cells than myocytes in all conditions.
Nitrotyrosine
Nitrotyrosine localization is shown in Figures 6A through 6F . In control muscles, the fraction of nitrotyrosine-positive cells was higher in myocytes than endothelial cells and fibroblasts. Diabetes doubled the percentages of myocytes and endothelial cells with nitrotyrosine; the frequency of labeled fibroblasts did not vary. To validate the cytochemical assay, control LV human myocardium was exposed to peroxynitrite before nitrotyrosine staining. Conversely, similar tissue sections were treated with degraded peroxynitrite before nitrotyrosine labeling. As expected, the first procedure resulted in a complete nitrotyrosine staining of the myocardium, whereas the second protocol left the tissue minimally labeled ( Figures  6G through 6J) . With diabetes and hypertension, 91% myocytes and 25% endothelial cells contained nitrotyrosine (Figure 6K) . A possible link between oxidative stress and cell death was determined (Figure 7 ) by evaluating 17 and 23 apoptotic myocytes and 15 and 14 apoptotic endothelial cells with D and DH, respectively. In all cases, apoptosis was accompanied by nitrotyrosine. Because of the high percentage of nitrotyrosine-positive myocytes in these hearts, the combination of nitrotyrosine and apoptosis was examined in control muscles; again, apoptosis was detected only in myocytes with nitrotyrosine (nϭ11). An identical association was established for myocyte (D, nϭ33; DH, nϭ65) and endothelial cell (D, nϭ15; DH, nϭ32) necrosis. Nitrotyrosine and DNA damage typical of necrosis was found in all cells. Finally, apoptotic (D, nϭ13; DH, nϭ10) and necrotic (D, nϭ14; DH, nϭ17) fibroblast death and the presence of nitrotyrosine were measured. This was done because the fraction of nitrotyrosine-positive fibroblasts did not increase with D or DH whereas the number of dying fibroblasts increased. All dying fibroblasts showed nitrotyrosine.
Discussion
Diabetes, Diabetes and Hypertension, and Heart Failure NIDDM led to myopathy in the absence of coronary artery disease and hypertension. Diabetes resulted in increased muscle mass, cavitary dilation, mural thinning, and depressed ventricular performance. These anatomical and functional characteristics reflect decompensated eccentric hypertrophy, 23 a condition that was more severe when diabetes and hypertension were present. However, diabetes produced these effects in half the period of diabetes and hypertension. This difference suggests that diabetes was better controlled in diabetic-hypertensive patients or that hypertension counteracted initially the consequences of diabetes on cardiac restructuring. Hypertension promotes an increase in wall thickness, 23 and early in the course of the disease, this hypertrophic response may have attenuated the expansion in chamber volume and diastolic dysfunction with diabetes. 15 This form of adaptation has been shown experimentally shortly after coronary artery constriction and renal hypertension. 24 Whether this type of apparent compensation actually occurs in humans is difficult to envision.
Complex is understanding how diabetes per se affects ventricular remodeling. At its onset, NIDDM results in myocardial hypertrophy and impaired cardiac function in spite of greater mass and thickened wall in humans. 25 This suggests that defects in muscle mechanical behavior are operative in diabetes. The depression in contractility occurs before the myopathy progresses to the phase analyzed here, in which myocardial scarring and ongoing cell death contributed to ventricular dilation, wall thinning, and depressed hemodynamics. The hypertensive 9,26 and diabetic-hypertensive heart evolve in a similar manner. Myocyte death is a shared pathological event that occurs chronically in the diseased heart, 19,27 but its actual role in the transition from compensated to decompensated hypertrophy and failure remains controversial. 28 Cell death is required for acute expansion in cavitary volume, and myocyte death and growth are critical determinants of cardiac remodeling of ischemic and nonischemic origin. 29 
Diabetes, Diabetes and Hypertension, and Cell Death
Apoptosis and necrosis were detected in myocytes, endothelial cells, and fibroblasts of the failing diabetic and diabetic-hypertensive heart. Myocyte and endothelial cell apoptosis varied from 0.06% to 0.07% in the 2 groups of patients, whereas myocyte and endothelial cell necrosis ranged from 0.07% to 0.1% with diabetes and from 0.15% to 0.18% with diabetes and hypertension. Apoptosis and necrosis involved lower fractions of fibroblasts. Cardiac cell apoptosis did not differ in patients with diabetes and with diabetes and hypertension. Conversely, necrosis of myocytes and endothelial cells was significantly higher with diabetes and hypertension than with diabetes alone. Necrosis of myocytes and endothelial cells was 1.4-and 2.5-fold higher than apoptosis with diabetes and diabetes and hypertension, respectively.
Myocyte death has previously been measured in end-stage cardiac failure by the methods used here. 19 However, in the terminal phases of cardiac decompensation, the values for apoptotic and necrotic myocytes were 3-and 7-fold higher, respectively. Moreover, the more compromised diabetichypertensive heart had a larger fraction of dying myocytes. These findings strengthen the notion that the extent of ongoing myocyte death parallels the severity of the disease and its stage of evolution. Endothelial cell death may have comparable implications. Myocytes and capillary endothelial cells, which are functionally interdependent and have a one-to-one ratio, 30 are similarly affected by apoptosis and necrosis in the failing human heart. Capillary density decreases in the hypertrophied heart in humans, 31 and endothelial cell death with loss of capillary units may be relevant to the progression of cardiac decompensation. Reduction in capillary number results in a decrease in capillary surface available for oxygen diffusion and transport and an increase in the diffusion distance for oxygen. 31 Alterations in the capillary properties controlling tissue oxygen distribution and consumption may lead to local ischemia and additional activation of cell-death mechanisms.
The identification of myocyte apoptosis in the heart in vivo has been challenged by electron microscopic analysis of tissue sections. 28 As used, electron microscopy does not permit adequate sampling and the results are uninterpretable. 32 The claim has also been made that molecular probes capable of identifying specific forms of DNA damage may result in an overestimation of apoptosis. 33 This conclusion was reached on the theoretical basis that probes may recognize cell death when only 10% of the double DNA strand breaks required for apoptosis are detected. This argument is weak; one unrepaired double-strand cleavage is sufficient to kill a cell. As emphasized previously, evaluation of apoptosis by 3 independent histochemical methods and confocal microscopy provides an accurate assessment of this form of cell death. 32 
Diabetes, Diabetes and Hypertension, and Ang II
The localization of Ang II increased in myocytes and capillary endothelial cells of diabetic and diabetic-hypertensive hearts. Ang II sites in these cells were 2-fold higher with diabetes and hypertension than with diabetes alone. Ang II labeling in endothelial cells was 5-to 6-fold greater than in myocytes. Stimulation of the cellular RAS occurred in spite of the fact that all patients were treated with ACE inhibitors. Diabetes and diabetes and hypertension activated the local RAS, and ACE inhibitors, directly or indirectly, blocked only in part the generation of Ang II at the cellular level. This is consistent with the limited capacity of ACE inhibitors to traverse the plasma membrane and abolish the cytoplasmic synthesis of Ang II. 34 However, it cannot be excluded that enhanced Ang II labeling reflected increased binding to endogenous receptors.
Clinical 15 and experimental 6 results indicate that diabetes is characterized by upregulation of the systemic and local RAS, and interventions attenuating the effects of Ang II positively interfere with morbidity, mortality, and the development of a diabetic myopathy. Ang II triggers cell death 35 and promotes cell growth, 36 which are present with diabetes and diabetes and hypertension. The difference in Ang II labeling between the diabetic and the diabetic-hypertensive heart is consistent with the difference in cardiac mass, myocyte cross-sectional area, replacement fibrosis, cell death, and ventricular performance found in these 2 groups of patients. Enhanced generation of Ang II in the myocardium may explain the increase in mural thickness and mass detected in diabetic Native Americans. 25 The mechanism activating the local RAS has not been identified. Angiotensinogen (Aogen) is the limiting factor in the synthesis of Ang II, 37 and p53 promotes transcription of Aogen and AT 1 , enhancing Ang II formation and Ang II-mediated responses in myocytes. 35, 37 These effects are blocked by losartan. Hyperglycemia may result in p53 glycosylation and expression of Aogen and AT 1 receptor. 6 On this basis, AT 1 blockade might be more beneficial than ACE inhibition in counteracting the impact of Ang II on cell growth and cell death with diabetes.
Diabetes, Diabetes and Hypertension, and Oxidative Stress
Nitric oxide (NO) can interact with superoxide-forming peroxynitrite. Peroxynitrite may decompose into oxidants with reactivity similar to hydroxyl radical-forming nitroty- rosine. 16 Nitrotyrosine may also derive from inflammatory cells and the interaction between myeloperoxidase and nitrogen dioxide, independently from NO. 38 Cell necrosis is associated with an inflammatory response surrounding the dying cell, but this phenomenon is apparent after DNA fragmentation has occurred. 19 Whether the accumulation of nitrotyrosine with diabetes and diabetes and hypertension was mediated by NO or other enzymatic pathways cannot be ascertained at present. However, with diabetes, nitrotyrosine increased in all cardiac cells and, with diabetes and hypertension, increased additionally in myocytes and endothelial cells. The percentage of myocytes expressing nitrotyrosine was much higher than endothelial cells and fibroblasts. In spite of the difference in nitrotyrosine, apoptosis and necrosis of myocytes, endothelial cells, and fibroblasts were detected exclusively in cells containing this modified amino acid. Thus, an association exists between oxidative stress and cell death with diabetes and diabetes and hypertension. However, the present observations do not allow to establish a causeand-effect relationship between these cellular events.
Studies in patients 10 and animals 11 have demonstrated a direct correlation between hyperglycemia and the production of reactive O 2 . Moreover, Ang II leads to an oxidative stress response through stimulation of NADH/NADPH oxidase. [12] [13] [14] This enzyme is the major source of superoxide via the transfer of electrons from NADH or NADPH to O 2 . 12 Such effects of Ang II are mediated through the AT 1 receptor. 14 On this basis, the possibility may be advanced that local increases in Ang II with diabetes and with diabetes and hypertension enhance oxidative damage, activating the death pathways implicated in cell apoptosis and necrosis. Different levels of reactive O 2 condition distinct forms of cell death: high amounts induce necrosis and low quantities trigger apoptosis. 39 
